Search clinical trials for: regorafenib (STIVARGA®)

Total 20297 results

Central DuPage Hospital
Zimmer Biomet; Halifax Biomedical Inc.

Unknown

A Prospective Radiostereometric Analysis and Clinical Evaluation of the Zimmer® Continuum® Acetabular Cup With Vitamin E Stabilized Polyethylene

Radiostereometric Analysis | Vitamin E Liner | Zimmer® Continuum® Acetabular Cup

United States
Incyte Corporation

Terminated

Study of Ruxolitinib in Colorectal Cancer Patients

CRC (Colorectal Cancer)

United States, France, United Kingdom, Spain, Israel, Australia, Germany, Korea, Democratic People's Republic of
Semmes-Murphey Foundation

Unknown

Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration

Pain | Degenerative Disc Disease

United States
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
M.D. Anderson Cancer Center
Bayer

Not yet recruiting

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Gastrointestinal Stromal Tumors

United States
Bayer

Completed

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Neoplasms

Canada, United States
Bayer

Completed

Regorafenib Phase I Study in Mainland Chinese Patients

Oncology

China
Bayer

Completed

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy (RECORA)

Colorectal Neoplasm

Germany
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb; Bayer

Active, not recruiting

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Esophagogastric Cancer | HER2-Negative

United States
Bayer

Completed

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Advanced Gastrointestinal Stromal Tumor

United States
Bayer

Active, not recruiting

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Solid Malignant Tumors

France, Japan, Taiwan, Korea, Republic of, Spain
Bayer

Completed

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States (COLONGER)

Metastatic Colorectal Cancer

United States
Bayer

Completed

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Neoplasms

United States
Hospital de Base

Not yet recruiting

Diagnostic Accuracy Study of a Point-of-Care Test for Coagulation Function

CoaguChek® XS System | Coagulation Function
Tianjin Medical University Cancer Institute and...

Recruiting

Bovine Pericardial Patch and TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction.

Implant Breast Reconstruction | TiLOOP® Bra Mesh | Bovine Pericardial Patch

China
King Abdulaziz University

Completed

Effect of Carriere® Motion™ Appliance on Airway Dimensions

Effect of Carriere® Motion™ Appliance on Pharyngeal Airway Dimensions | Effect of Carriere® Motion™ Appliance on Skeletal and Dental Measurements

Saudi Arabia
Eureka Therapeutics Inc.

Recruiting

T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3)

Hepatocellular Carcinoma | Liver Neoplasm | Metastatic Liver Cancer | Liver Cancer, Adult

United States
Allergan

Completed

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

Patients Who Participated in an Intravitreal Brimo PS DDS® Study

France, United Kingdom, Korea, Republic of, Czech Republic, Australia, Israel, India, Portugal, Germany, United States, Italy, Philippines
Bayer

Completed

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS)

Colorectal Neoplasms

Korea, Republic of
Bayer

Completed

Regorafenib Post-marketing Surveillance in Japan

Gastrointestinal Stromal Tumors

Japan
Bayer

Completed

Stivarga Real Life Evidence in Hungary

Colorectal Neoplasms

Hungary
Bayer

Completed

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Pharmacokinetics | Dietary Fats

United States
Johanna Maria Vermeulen
Nanjing University of Chinese Medicine; Mermaid Medicine®

Completed

Acupuncture for Nasal Congestion in Allergic Rhinitis (ANCAR)

Allergic Rhinitis

Netherlands
Pierre Fabre Dermo Cosmetique

Completed

Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic Subjects

Acne

Portugal
Central Clinical Hospital of the Ministry of Internal...

Completed

First-in-man Sirolimus-eluting Prolim® Stent Registry

Sirolimus-eluting Stainless Steel Coronary Stent Prolim®
TriHealth Inc.

Completed

Long-term Usage of the Fitbit® Among Medical Residents

Continuous Fitbit® Use
Bayer

Completed

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy (REGARD)

Colorectal Neoplasms

Turkey
B.Braun Médical - CoE Chasseneuil

Not yet recruiting

The Performance / Safety of the Celsite® Venous Access Ports (CAP)

The Performance / Safety of the Celsite® Venous Access Ports
Galderma R&D

Completed

ORCA - Oracea® for Rosacea: A Community-based Assessment

Rosacea

United States
University of Rochester
Bayer

Completed

Regorafenib in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Bayer

Completed

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Carcinoma, Renal Cell

United States, France, United Kingdom, Finland, Germany, Poland
Bayer

Completed

Safety and Effectiveness of Regorafenib (Correlate)

Neoplasms

Austria, Czechia, Switzerland, Italy, France, Mexico, Singapore, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Argentina
Incyte Corporation

Active, not recruiting

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Breast Cancer | Pancreatic Cancer | Lung Cancer | Colorectal Cancer (CRC)

United States, Poland
Institute of Mother and Child, Warsaw, Poland
Maria Sklodowska-Curie National Research Institute of Oncology

Recruiting

Regorafenib in Patients With Refractory Primary Bone Tumors (Regbone)

Osteosarcoma | Ewing Sarcoma of Bone

Poland
Massachusetts General Hospital
Bayer

Completed

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Acute Myeloid Leukemia

United States
Grupo Espanol de Investigacion en Sarcomas
Bayer

Completed

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)

Gastrointestinal Stromal Tumors

Spain, France, Italy
Duquesne University
OsteoStrong

Active, not recruiting

Melatonin and Osteogenic Loading on Osteopenia (MelaOstrong)

Osteopenia

United States
Piramal Enterprises Limited
Profil Institute for Clinical Research, Inc.

Completed

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

Healthy

United States
Bayer

Completed

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib (COLONG)

Colorectal Neoplasms

Belgium
Istituto Oncologico Veneto IRCCS

Completed

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Glioblastoma Multiforme

Italy
Bayer

Completed

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Metastatic Colorectal Cancer

India
National Cancer Centre, Singapore

Completed

Use of Regorafenib in Recurrent Epithelial Ovarian Cancer

Ovarian Neoplasms

Singapore
Royal Marsden NHS Foundation Trust
Bayer

Completed

Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy (PROSPECT-R)

Metastatic Colorectal Cancer

United Kingdom
University of Pittsburgh
Merck Sharp & Dohme LLC; RTI International; Rite Aid Corp.; Pharmacy Quality Alliance

Completed

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications (ECO-PHIL)

Medication Adherence

United States
Hadassah Medical Organization

Completed

Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth.

Pulpotomies Primary Teeth | Effectiveness of MedCem MTA® in Pulpotomies Primary Teeth

Israel
Dana-Farber Cancer Institute
Bayer

Active, not recruiting

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Thyroid Cancer

United States
Istituto Clinico Humanitas

Completed

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy (RESOUND)

Melanoma | Sarcoma | Ovarian Cancer | Thymic Carcinoma | Pancreas Cancer | Thymoma Type B3 | Thymoma Type B2

Italy
Nathan Bahary, MD
Bayer

Completed

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Metastatic Biliary Tract Carcinoma

United States
Asan Medical Center

Unknown

[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib

Colorectal Cancer

Korea, Republic of
Georgetown University
Bayer

Terminated

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

Colon Cancer

United States

Search clinical trials for: regorafenib (STIVARGA®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations